In mouse models and human tissue, GATA2 expression increased with the development of CRPC (Hendriksen et al. 2006, Wang et al. 2009, Vidal et al. 2015), and expression levels are associated with prostate cancer aggression and outcome in patient cohorts (Bohm et al. 2009, He et al. 2014). This evidence concerns the gene GATA2 and prostate carcinoma.